Skip to main content

Advertisement

SpringerLink
Log in

Isolated systolic hypertension and the risk of vascular disease

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension is present in 60% to 70% of the population over 60 years of age and may result in cardiovascular complications such as stroke, coronary heart disease, and heart failure. In this review, the role of arterial stiffness, endothelial function, atherosclerosis, and oxidative stress in the pathogenesis of hypertension is discussed extensively. Antihypertensive drug treatment may control high blood pressure and prevent complications. This review summarizes the results of several placebo-controlled and comparative clinical trials that have studied the efficacy of different classes of antihypertensive drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Staessen J, Amery A, Fagard R: Editorial review. Isolated systolic hypertension in the elderly. J Hypertens 1990, 8:393–405.

    Article  PubMed  CAS  Google Scholar 

  2. Franklin SS, Larson MG, Khan SA, et al.: Does the relation of blood pressure to coronary heart disease change with aging? Circulation 2001, 103:1245–1249. This epidemiologic study shows that with increasing age there is a gradual shift from diastolic to systolic and then to pulse pressure as predictor of coronary heart disease risk. The strength of the study is the large number of subjects (> 6500) in a wide age range (20-79 years) with a 20-year follow-up.

    PubMed  CAS  Google Scholar 

  3. Staessen JA, Gasowski J, Wang JG, et al.: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355:865–872. This meta-analysis estimates the risk for total mortality and cardiovascular events in patients with isolated systolic hypertension. The paper confirms risk reduction scores found in epidemiologic studies and also gives subgroup analyses by sex, age, previous complications, smoking, SBP, and pulse pressure.

    Article  PubMed  CAS  Google Scholar 

  4. Mitchel GF, Moyé LA, Braunwald E, et al., for the SAVE Investigators: Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation 1997, 96:4254–4260.

    Google Scholar 

  5. Safar ME, Blacher J, Pannier B, et al.: Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002, 39:735–738.

    Article  PubMed  CAS  Google Scholar 

  6. Blacher J, Staessen JA, Girerd X, et al.: Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000, 160:1085–1089.

    Article  PubMed  CAS  Google Scholar 

  7. Staessen JA, Thijs L, O’Brien ET, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens 2002, 15(part 1):835–843.

    Article  PubMed  Google Scholar 

  8. Guidelines Committee: ESH hypertension guidelines. J Hypertens 2003, In press.

  9. Vasan RS, Larson MG, Leip EP, et al.: Assessment of frequency to progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358:1682–1686. This study showed that approximately 40% of the persons with high-normal blood pressure below the age of 65 years will develop hypertension over a period of 4 years.

    Article  PubMed  CAS  Google Scholar 

  10. Asmar R, Safavian A, Tual JL, Safar ME: Arterial and cardiac changes in hypertension in the elderly. Blood Press Suppl 1995, 3:31–37.

    PubMed  CAS  Google Scholar 

  11. Schocken DD, Roth GS: Reduced beta-adrenergic receptor concentrations in ageing man. Nature 1977, 267:856–8.

    Article  PubMed  CAS  Google Scholar 

  12. Thompson J, Khalil RA: Gender differences in the regulation of vascular tone. Clin Exp Pharmacol Physiol 2003, 30:1–15.

    Article  PubMed  CAS  Google Scholar 

  13. Heintz B, Dorr R, Gillessen T, et al.: Do arterial endothelin 1 levels affect local arterial stiffness? Am Heart J 1993, 126:987–989.

    Article  PubMed  CAS  Google Scholar 

  14. Hallock P, Benson IC: Studies on the elastic properties of human isolated aorta. J Clin Invest 1937, 16:595–602.

    Article  PubMed  CAS  Google Scholar 

  15. M’Buyamba-Kabangu JR, Fagard R, et al.: Blood pressure and urinary cations in urban Bantu of Zaire. Am J Epidemiol 1986, 124:957–968.

    PubMed  CAS  Google Scholar 

  16. Liao D, Arnett DK, Tyroler HA, et al.: Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 1999, 34:201–206.

    PubMed  CAS  Google Scholar 

  17. Benetos A, Okuda K, Lajemi M, et al.: Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001, 37:381–385. This study shows that telomeres, a marker of biologic age, are associated with pulse pressure and pulse wave velocity in men independent from chronologic age. It suggests that pulse pressure and pulse wave velocity are markers of the biologic age of the vascular.

    CAS  Google Scholar 

  18. Aviv A, Aviv H: Reflections on telomeres, growth, aging, and essential hypertension. Hypertension 1997, 29:1067–1072.

    PubMed  CAS  Google Scholar 

  19. Stein JH, McBride PE: Hyperhomocysteinemia and atherosclerotic vascular disease. Pathophysiology, screening and treatment. Arch Intern Med 1998, 158:1301–1306.

    Article  PubMed  CAS  Google Scholar 

  20. Xu D, Neville R, Finkel T: Homocysteine accelerates endothelial cell senescence. FEBS Lett 2000, 470:20–24.

    Article  PubMed  CAS  Google Scholar 

  21. Mark AL, Correia M, Morgan DA, et al.: State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999, 33:5375–41.

    Google Scholar 

  22. Lehmann ED, Hopkins KD, Gosling RG: Aortic compliance measurements using Doppler ultrasound: in vivo biochemical correlates. Ultrasound Med Biol 1993, 19:683–710.

    Article  PubMed  CAS  Google Scholar 

  23. Mertens A, Holvoet P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001, 15:2073–2084. This review focus on the presence of different forms of oxidatively modified low-density lipoprotein in the circulation and their relation to cardiovascular disease.

    Article  PubMed  CAS  Google Scholar 

  24. Mahmud A, Feely J: Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension 2003, 41:183–187.

    Article  PubMed  CAS  Google Scholar 

  25. Prisco D, Fedi S, Brunelli T, et al.: The influence of smoking on von Willebrand factor is already manifest in healthy adolescent females: the Floren-teen (Florence Teenager) Study. Int J Clin Lab Res 1999, 29:150–154.

    Article  PubMed  CAS  Google Scholar 

  26. Winniford MD: Smoking and cardiovascular function. J Hypertens 1990, 8(Suppl):S17-S23.

    CAS  Google Scholar 

  27. Wiltshire EJ, Gent R, Hirte C, et al.: Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes 2002, 51:2282–2286.

    Article  PubMed  CAS  Google Scholar 

  28. Larsen ML, Horder M, Mogensen EF: Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990, 323:1021–1025.

    Article  PubMed  CAS  Google Scholar 

  29. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042–1050.

    Article  PubMed  CAS  Google Scholar 

  30. Bortolotto LA, Safar ME, Billaud E, et al.: Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 1999, 34:837–842.

    PubMed  CAS  Google Scholar 

  31. van Guldener C, Lambert J, ter Wee PM, et al.: Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy. Clin Nephrol 2000, 53:33–41.

    PubMed  Google Scholar 

  32. van Dijk RA, Rauwerda JA, Steyn M, et al.: Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001, 21:2072–2079.

    PubMed  Google Scholar 

  33. Staessen JA, Thijs L, Fagard R, et al., for the Systolic Hypertension in Europe Trial Investigators: Predicting cardiovascular risk using conventional and ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999, 282:539–546.

    Article  PubMed  CAS  Google Scholar 

  34. Ohkubo T, Imai Y, Tsuji I, et al.: Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998, 16:971–975.

    Article  PubMed  CAS  Google Scholar 

  35. Kario K, Pickering TG, Matsuo T, et al.: Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001, 38:852–857.

    PubMed  CAS  Google Scholar 

  36. Verdecchia P, Staessen J, White WB, et al.: Properly defining white coat hypertension. Eur Heart J 2002, 23:106–109.

    Article  PubMed  CAS  Google Scholar 

  37. Verdecchia P, Schillaci G, Borgioni C, et al.: Ambulatory pulse pressure. A potent predictor of total cardiovascular risk in hypertension. Hypertension 1998, 32:983–988.

    PubMed  CAS  Google Scholar 

  38. Fagard RH, Staessen JA, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000, 102:1139–1144.

    PubMed  CAS  Google Scholar 

  39. Sega R, Trocino G, Lanzarotti A: Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2002, 104:1385–1392.

    Google Scholar 

  40. Staessen JA, Byttebier G, Buntinx F, et al., for the Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators: Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. JAMA 1997, 278:1065–1072.

    Article  PubMed  CAS  Google Scholar 

  41. Wu K, Xie L, Chen D, Chen J: The natural history of borderline hypertension in a Chinese population. J Hum Hypertens 1997, 11:95–100.

    Article  PubMed  CAS  Google Scholar 

  42. Gillum RF: The epidemiology of cardiovascular disease in black Americans. N Engl J Med 1996, 335:1597–598.

    Article  PubMed  CAS  Google Scholar 

  43. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765–774.

    Article  PubMed  CAS  Google Scholar 

  44. Stokes J, Kannel WB, Wolf PA, et al.: Blood pressure as a risk factor for cardiovascular disease. The Framingham Study - 30 years of follow-up. Hypertension 1989, 13(Suppl I):113–118.

    Google Scholar 

  45. Staessen JA, Thijs L, Birkenhäger WH, et al., on behalf of the Syst-Eur Investigators: Update on the Systolic Hypertension in Europe (Syst-Eur) Trial. Hypertension 1999, 33:1476–1477.

    PubMed  CAS  Google Scholar 

  46. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757–764 [correction published in Lancet 1997, 350:1636].

    Article  PubMed  CAS  Google Scholar 

  47. Voyaki SM, Staessen JA, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001, 19:511–19.

    Article  PubMed  CAS  Google Scholar 

  48. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Subgroup and per-protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Arch Intern Med 1998, 158:1681–1691.

    Article  PubMed  CAS  Google Scholar 

  49. Staessen JA, Thijs L, Fagard RH, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998, 32:410–416.

    PubMed  CAS  Google Scholar 

  50. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677–684.

    Article  PubMed  CAS  Google Scholar 

  51. Forette F, Seux ML, Staessen JA, et al., on behalf of the Syst-Eur Investigators: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347–1351.

    Article  PubMed  CAS  Google Scholar 

  52. Forette F, Seux ML, Staessen JA, et al., for the Syst-Eur Investigators: The prevention of dementia with antihypertensive treatment. New evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Intern Med 2002, 162:2046–2052.

    Article  PubMed  Google Scholar 

  53. Parnetti L, Senin U, Mecocci P: Cognitive enhancement therapy for Alzheimer’s disease. The way forward. Drugs 1997, 53:752–768.

    Article  PubMed  CAS  Google Scholar 

  54. Gueyffier F, Bulpitt C, Boissel JP, et al., for the INDANA Group: Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999, 353:793–796.

    Article  PubMed  CAS  Google Scholar 

  55. Beckett NS, Connor M, Sadler JD, et al., on behalf of the HYVET Investigators: Orthostatic fall in blood pressure in the very elderly hypertensive: results from the Hypertension in the Very Elderly Trial (HYVET) - pilot. J Hum Hypertens 1999, 13:839–840.

    Article  PubMed  CAS  Google Scholar 

  56. Staessen JA, Wang JG, Brand E, et al.: Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens 2001, 19:1349–1358.

    Article  PubMed  CAS  Google Scholar 

  57. Himmelmann A, Hedner T, Hansson L, et al.: Isolated systolic hypertension: an important cardiovascular risk factor. Blood Press 1998, 7:197–207.

    Article  PubMed  CAS  Google Scholar 

  58. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305–1315 [correction published in Lancet 2002, 359:360]. This meta-regression analysis shows that the benefits of antihypertensive therapy largely depend on blood pressure lowering. This paper could not confirm the hypothesis that newer antihypertensive drugs influence cardiovascular prognosis over and beyond their blood pressure-lowering effects.

    Article  PubMed  CAS  Google Scholar 

  59. Hansson L, Lindholm LH, Ekbom T, et al., for the STOP-Hypertension-2 Study Group: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751–1756.

    Article  PubMed  CAS  Google Scholar 

  60. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 2000, 317:713–720.

    Google Scholar 

  61. Dahlöf B, Devereux RB, Kjeldsen SE, et al., for The LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  Google Scholar 

  62. Wing LMH, Reid CM, Ryan P, et al., for the Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583–592.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department voor Moleculair en Cardiovasculair Onderzoek, Studiecoördinatiecentrum, Laboratorium Hypertensie, Campus Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium

    Tim Nawrot MSc

Authors
  1. Tim Nawrot MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elly Den Hond PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lutgarde Thijs MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan A. Staessen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nawrot, T., Den Hond, E., Thijs, L. et al. Isolated systolic hypertension and the risk of vascular disease. Current Science Inc 5, 372–379 (2003). https://doi.org/10.1007/s11906-003-0082-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0082-1

Keywords

Search

Navigation